Viruses (Oct 2023)

Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields

  • Leili Baghaie,
  • Fleur Leroy,
  • Mehdi Sheikhi,
  • Abdollah Jafarzadeh,
  • Myron R. Szewczuk,
  • Abdolkarim Sheikhi

DOI
https://doi.org/10.3390/v15102079
Journal volume & issue
Vol. 15, no. 10
p. 2079

Abstract

Read online

Mutations and the glycosylation of epitopes can convert immunogenic epitopes into non-immunogenic ones via natural selection or evolutionary pressure, thereby decreasing their sensitivity to neutralizing antibodies. Based on Thomas Francis’s theory, memory B and T cells induced during primary infections or vaccination will freeze the new mutated epitopes specific to naïve B and T cells from the repertoire. On this basis, some researchers argue that the current vaccines derived from the previous strains of the SARS-CoV-2 virus do not increase immunity and may also prevent the immune response against new epitopes. However, evidence shows that even if the binding affinity is reduced, the previous antibodies or T cell receptors (TCRs) can still bind to this new epitope of the Beta, Gamma, and Delta variant if their concentration is high enough (from a booster injection) and neutralize the virus. This paper presents some convincing immunological reasons that may challenge this theory and argue for the continuation of universal vaccination to prevent further mutations of the SARS-CoV-2 virus. Simultaneously, the information presented can be used to develop vaccines that target novel epitopes or create new recombinant drugs that do not lose their effectiveness when the virus mutates.

Keywords